Intelence (etravirine) is an antiretroviral medication indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in treatment-experienced adult patients. Intelence was FDA approved on January 8, 2008 and is marketed by Janssen Therapeutics, Division of Janssen Products, LP.

From 11/01/1997 to 08/27/2012, there have been 378 reports of a serious adverse event where INTELENCE was identified as the primary suspect drug causing that event. During that time period, the top three adverse events reported in cases where INTELENCE was identified as the primary suspect drug were: Rash, Pyrexia and Drug Interaction.

03/27/2012 - FDA Approves Intelence for Treatment-Experienced Pediatric Patients with HIV-1

Etravirine, R165335-TMC125, TMC125

Average Age: 46 Years
Gender: 71% M, 29% F
Average Duration of Treatment: 783 Days

Blinded; Tmc125
Emtravirine
Entravirine
Etravine Unk
Etravirin
Etravirine
Etravirine (all Other Therapeutic Products)
Etravirine (etravirine)
Etravirine (formulation Unknown) (etravirine)
Etravirine 100 Mg Tab Tibotec
Etravirine 100 Mg Tibotec
Etravirine 100 Mg Tibotec Etravirine
Etravirine 100mg J+j
Etravirine 100mg J+j
Etravirine 200mg Tibotec
Etravirine Unk
Etravirine(etravirine)
Intelence
Intelence (tablets)
Intellence
Tab Etravinine
Tab Etravirine
Tab Etravirine 100 Mg
Tab Etravirine 200 Mg/bid Po
Tab Etravirine Unk
Tab Tmc-125 (etravirine
Tab Tmc-125 (etravirine)
Tmc 125
Tmc 125 (blinded)
Tmc 125 (etravirine)
Tmc 125/placebo
Tmc-125
Tmc-125 (blinded)
Tmc-125 (etravirine)
Tmc-125(placebo)
Tmc125
Tmc125 (etravirine)
Tmc125 (blinded)
Tmc125 (open Label)
Tmc125 (placebo)
Tmc125()
Tmc125(blinded)
Show All

Tibotec Pharmaceuticals, Ltd. (304)
Johnson & Johnson (64)
McNEIL-PPC, Inc. (2)